| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | Mutated tissue plasminogen activators and uses thereof | US14972268 | 2015-12-17 | US09732334B2 | 2017-08-15 | Denis Vivien; Jerome Parcq |
| The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | ||||||
| 142 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | US15467404 | 2017-03-23 | US20170202932A1 | 2017-07-20 | Gary David HOUSLEY; Youngsoo Kim; Paul Page BERTRAND; Andrew MOORHOUSE; Ann Chi Yan Wong; Amanda Jayne CRAIG; John POWER; Matthias KLUGMANN; Arun KRISHNAN; Renee MORRIS |
| The present invention relates generally to methods for inhibiting neuron apoptosis and necrosis associated with excess glutamate release. | ||||||
| 143 | MAGNETIC PARTICLE CONTROL | US15160944 | 2016-05-20 | US20170128571A1 | 2017-05-11 | Francis M. Creighton |
| Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. | ||||||
| 144 | Multi-arm linker constructs for treating pathological blood clots | US15212298 | 2016-07-18 | US09623118B2 | 2017-04-18 | Tse-Wen Chang; Hsing-Mao Chu; Chun-Yu Lin |
| The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed. | ||||||
| 145 | NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE | US15079550 | 2016-03-24 | US20170051268A1 | 2017-02-23 | Mariola SOHNGEN; Wolfgang SOHNGEN; Wolf-Dieter SCHLEUNING; Robert MEDCALF |
| The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans. | ||||||
| 146 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | US15225819 | 2016-08-01 | US20170007712A1 | 2017-01-12 | Shawn DeFrees; David A. Zopf; Robert J. Bayer; David Hakes; Caryn L. Bowe; Xi Chen |
| The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | ||||||
| 147 | PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE | US15136614 | 2016-04-22 | US20160310580A1 | 2016-10-27 | Maheshwari Kumar MISHRA; Pritiranjan BHANDARI; Sanjay SINGH |
| Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke. | ||||||
| 148 | BLOOD CLOT-DISSOLVING PROTEINS PRODUCED IN SEEDS | US15002087 | 2016-01-20 | US20160208274A1 | 2016-07-21 | Kevin Yueju Wang |
| Transgenic plants in which blood-clot dissolving proteins are produced in seeds of the plants are provided. Expression of the proteins is driven by a seed specific or selective promoter. Exemplary blood-clot dissolving proteins produced in this manner include recombinant Desmodus rotundus salivary plasminogen activator α1 (DSPAα1) and recombinant human tissue plasminogen activator (t-PA). Recombinant proteins isolated from seeds dissolved blood clots. | ||||||
| 149 | METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS | US14949266 | 2015-11-23 | US20160144001A1 | 2016-05-26 | Douglas E. Vaughan; Mesut Eren; Aaron T. Place; Toshio Miyata |
| The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA. | ||||||
| 150 | Gelatinase inhibitors and prodrugs | US14567480 | 2014-12-11 | US09321754B2 | 2016-04-26 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 151 | STEROIDAL NITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA, ALZHEIMER AND PARKINSON DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS | US14892755 | 2014-05-22 | US20160089382A1 | 2016-03-31 | José Luis Marco Contelles; Alberto Alcázar González |
| The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and amyotrophic lateral sclerosis. | ||||||
| 152 | HETEROMULTIVALENT PARTICLE COMPOSITIONS | US14827785 | 2015-08-17 | US20160015833A1 | 2016-01-21 | ANIRBAN SEN GUPTA; Madhumitha Ravikumar; Christa Modery |
| A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | ||||||
| 153 | TREATMENT FOR AIRWAY CAST OBSTRUCTION | US14649238 | 2013-12-05 | US20150322421A1 | 2015-11-12 | Carl W. WHITE; Livia A. VERESS |
| The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent. | ||||||
| 154 | DIAGNOSTIC MARKER FOR TREATMENT OF CEREBRAL ISCHEMIA | US14657777 | 2015-03-13 | US20150258193A1 | 2015-09-17 | Lawrence M. KAUVAR; Damir JANIGRO |
| Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity. | ||||||
| 155 | PKC activators and anticoagulant in regimen for treating stroke | US13178843 | 2011-07-08 | US09107890B2 | 2015-08-18 | Daniel L. Alkon |
| The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke. | ||||||
| 156 | METHODS FOR INHIBITING NEURON APOPTOSIS AND NECROSIS | US14412793 | 2013-07-05 | US20150190366A1 | 2015-07-09 | Gary David Housley; Youngsoo Kim; Paul Page Bertrand; Andrew Moorhouse; Ann Chi Yan Wong; Amanda Jayne Craig; John Power; Matthias Klugmann; Arun Krishnan; Renee Morris |
| The present invention relates generally to methods for inhibiting neuron apoptosis and necrosis associated with excess glutamate release. | ||||||
| 157 | CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF | US14594821 | 2015-01-12 | US20150183844A1 | 2015-07-02 | Byron D. FORD |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
| 158 | CONTROL OF MAGNETIC ROTORS TO TREAT THERAPEUTIC TARGETS | US14268244 | 2014-05-02 | US20150099919A1 | 2015-04-09 | Francis M. Creighton |
| A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels. | ||||||
| 159 | GELATINASE INHIBITORS AND PRODRUGS | US14567480 | 2014-12-11 | US20150093372A1 | 2015-04-02 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 160 | Chimeric neuregulins and method of making and use thereof | US13865812 | 2013-04-18 | US08933034B2 | 2015-01-13 | Byron D. Ford |
| Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin. | ||||||
QQ群二维码
意见反馈
意见反馈